Aptadir Therapeutics
PrivateLast Round
Seed
Sep 29, 2026
Total Funding Raised
$46.6M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Aptadir Therapeutics is a biotechnology company developing a novel class of RNA inhibitor-based therapeutics designed to reactivate genes silenced through aberrant DNA methylation for the treatment of genetic disorders and oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aptadir Therapeutics Comparables
Compare Aptadir Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Iris Medicine | 83% | |
| Replicate Bioscience | 82% | |
| HAYA Therapeutics | 81% |
Aptadir Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Sep 29, 2026 | ||||
| Pre Seed | Sep 24, 2024 |
Key People
Founding team and executive leadership
Aptadir Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| XGEN Venture | Seed |
| CE-Ventures | Seed |
| Indaco Venture Partners SGR | Seed |
| 4BIO Capital | Seed |
| Club degli Investitori | Seed |
| Italian Angels for Biotech | Seed |
| Angelini Ventures | Pre Seed, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 29, 2026
$45M round led by 4BIO Capital.
- Jan 1, 2026
Monthly visitors increased 127% MoM.
Recent news
Latest coverage and updates
- is_developingOct 1, 2026
Aptadir develops a novel class of RNA inhibitors (DiRs) in Italy
- is_developingSep 29, 2026
Aptadir is developing CAP1-FMR1 on Sep 29th '26.
- is_developingSep 29, 2026
Aptadir is developing portfolio of drug candidates.
- receives_financingSep 29, 2026
Aptadir raises $45.5M Seed round in Italy on Sep 29th '26
Aptadir Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Aptadir Therapeutics's valuation, stock price, and market status.
Is Aptadir Therapeutics a public or private company?
Aptadir Therapeutics is a private company.
What is the current stock price of Aptadir Therapeutics?
Aptadir Therapeutics is a private company with no public stock price. Caplight tracks Aptadir Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.
How much is Aptadir Therapeutics worth (valuation)?
Valuation information for Aptadir Therapeutics is not publicly available.
Can I buy Aptadir Therapeutics stock?
Aptadir Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Aptadir Therapeutics's last funding round?
Aptadir Therapeutics's most recent funding round was Seed on September 29, 2026.
Who are the main investors in Aptadir Therapeutics?
Key investors in Aptadir Therapeutics include 4BIO Capital.
Will Aptadir Therapeutics IPO soon?
No public IPO plans have been announced for Aptadir Therapeutics.
How can I track Aptadir Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Aptadir Therapeutics's secondary market activity and sign up for updates.